^
Association details:
| Biomarker: | TGFB1 underexpression |
|---|---|
| Cancer: | Biliary Tract Cancer |
| Drug: | AiRuiKa (camrelizumab) (PD1 inhibitor) + AiTan (rivoceranib) (VEGFR-2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Biomarker analysis of first-line camrelizumab plus apatinib in patients with advanced biliary tract cancers: Results from a phase II study.
Published date:
05/26/2022
Excerpt:
Fourteen advanced BTCs patients from the single-arm phase II study (ChiCTR2000034283) receiving camrelizumab (anti-PD-1 antibody) plus apatinib (VEGFR2 inhibitor) as first-line combination therapy, were included for the current biomarkers analysis….Differential gene expression analysis revealed a significantly higher BRCA2, RAD51, BRIP1 expression (p < 0.001) and decreased TGFβ1, ITGAX, ITGB2 expression (p < 0.001) in responder tumors compared with non-responder tumors.
DOI:
10.1200/JCO.2022.40.16_suppl.e16164
